Mumbai, Maharashtra

GST No. 27AAICT4656Q1ZG

Send Email
0794296522380% Response Rate
Search

Home » Products & Services » Nephrology Medicines


Nephrology Medicines

Providing you the best range of sirolimus tablets 1mg with effective & timely delivery.

Sirolimus Tablets 1mg

REQUEST CALLBACK

Sirolimus Tablets 1mg
  • Sirolimus Tablets 1mg
  • Sirolimus Tablets 1mg
  • Sirolimus Tablets 1mg
Get Best Quote

Thanks for Contacting Us.

Approx. Rs 650 / StripeGet Latest Price

Product Details:
Strength1 mg
Packaging Size10 Tablets
Usage/ApplicationClinical
Packaging TypeFinished
FormTablet
BrandRapacan
ManufacturerBiocon
Dose/Strength1 mg
Country of OriginMade in India

Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumor (PEComa). It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It is a mechanistic target of rapamycin kinase (mTOR) inhibitor[2] that inhibits activation of T cells and B cells by reducing their sensitivity to interleukin-2 (IL-2).

It is produced by the bacterium Streptomyces hygroscopicus and was isolated for the first time in 1972, from samples of Streptomyces hygroscopicus found on Easter Island. The compound was originally named rapamycin after the native name of the island, Rapa Nui. Sirolimus was initially developed as an antifungal agent. However, this use was abandoned when it was discovered to have potent immunosuppressive and antiproliferative properties due to its ability to inhibit mTOR. It was approved by the U.S. Food and Drug Administration (FDA) in September 1999

 

Sirolimus is indicated for the prevention of organ transplant rejection and for the treatment of lymphangioleiomyomatosis (LAM).

Sirolimus (Fyarro), as protein-bound particles, is indicated for the treatment of adults with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa)

The most common adverse reactions (≥30% occurrence, leading to a 5% treatment discontinuation rate) observed with sirolimus in clinical studies of organ rejection prophylaxis in individuals with kidney transplants include: peripheral edema, hypercholesterolemia, abdominal pain, headache, nausea, diarrhea, pain, constipation, hypertriglyceridemia, hypertension, increased creatinine, fever, urinary tract infection, anemia, arthralgia, and thrombocytopenia.

The most common adverse reactions (≥20% occurrence, leading to an 11% treatment discontinuation rate) observed with sirolimus in clinical studies for the treatment of lymphangioleiomyomatosis are: peripheral edema, hypercholesterolemia, abdominal pain, headache, nausea, diarrhea, chest pain, stomatitis, nasopharyngitis, acne, upper respiratory tract infection, dizziness, and myalgia.[

Yes! I am Interested

 
X


Explore More Products

Contact via E-mail
Contact via SMS
Tom (CEO)
Toro Pharmaceuticals Private Limited
Plot - 10 and 11,Thakker Industrial Estate, Sitaram Mill Compound,N M Joshi Marg,Mumbai,4D, Floor-4
Mumbai - 400011, Maharashtra, India
Call Us: 
Call Response Rate: 80%
Share Us :



© Toro Pharmaceuticals Private Limited. All Rights Reserved (Terms of Use)
Developed and Managed by IndiaMART InterMESH Limited

Toro Pharmaceuticals Private Limited